VasoMedical Launches New and Updated Web Sites

New Look with Easy Access to More Information

August 21, 2012 - WESTBURY, NY – VasoMedical, Inc. (“VasoMedical”) (OTC: VASO.QB), a leader in the manufacture and sale of devices for the non-invasive treatment and management of cardiovascular diseases and a leader in the sale of diagnostic imaging products, today announced the launch of its new and updated web sites which reflect the restructuring of the Company, as previously reported. The web sites have been designed to provide greater and easier access to updated information for patients, customers, investors and the general public about the Company, its technologies and expertise, and product offerings. ( will continue as the corporate web site for the parent company. ( is the web site for the newly formed operating subsidiary VasoMedical Solutions, which manages and coordinates the Company's EECP® Therapy and other medical products operations. ( will continue as the web site for Vaso Diagnostics, Inc., d/b/a/ VasoHealthcare, the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products. The ( is the new web site for VasoMedical Global Corp. which operates the Company's Chinese subsidiaries and ( is the newly created web site for the dissemination and promotion of clinical information about the Company's core technology, Enhanced External Counterpulsation (EECP®).

“As our Company grows to meet the needs and challenges of today's healthcare market we will continue to provide easier access to valuable content and information about ourselves and our products” stated Larry Liebman, Vice President of Sales and Marketing. He continued “A new look for our Company demands a new look for our web sites whose design and function provide easier navigation and a beneficial experience for all visitors to the sites.”

The new and updated web sites launch has been timed to coincide with VasoMedical's exhibition of its EECP® Therapy and BIOXTM ECG Holter/Ambulatory Blood Pressure Monitoring products at the European Society of Cardiology in Munich, Germany August 24-28, 2012. The Company will exhibit and demonstrate its products at the Messe Munich Exhibition in Hall 2 Booth #C-530.

About Vasomedical

VasoMedical, Inc. is a diversified medical technology company specializing in the manufacture and sale of medical devices and in the domestic sale of diagnostic imaging products. The Company operates through three wholly-owned subsidiaries. VasoMedical Solutions manages and coordinates the design, manufacture and sales of EECP® Therapy systems, its core product, as well as other medical equipment operations; VasoMedical Global operates the Company's China-based subsidiaries; and Vaso Diagnostics, d/b/a VasoHealthcare, is the operating subsidiary for the sales representation of GE Healthcare diagnostic imaging products. Additional information is available on the Company's website at

Except for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the effect of the dramatic changes taking place in the healthcare environment; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in the conduct of clinical trials and other product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; uncertainties about the acceptance of a novel therapeutic modality by the medical community; continuation of the GEHC agreement; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

Home | Back to News

©2017 Vaso Corporation